Unknown

Dataset Information

0

Percutaneous Intervention or Bypass Graft for Left Main Coronary Artery Disease? A Systematic Review and Meta-Analysis.


ABSTRACT: Background:The safety and efficacy of percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG) for stable left main coronary artery disease (LMCAD) remains controversial. Methods:Digital databases were searched to compare the major adverse cardiovascular and cerebrovascular events (MACCE) and its components. A random effect model was used to compute an unadjusted odds ratio (OR). Results:A total of 43 studies (37 observational and 6 RCTs) consisting of 29,187 patients (PCI 13,709 and CABG 15,478) were identified. The 30-day rate of MACCE (OR, 0.56; 95% CI, 0.42-0.76; p?=?0.0002) and all-cause mortality (OR, 0.52; 95% CI, 0.30-0.91; p?=?0.02) was significantly lower in the PCI group. There was no significant difference in the rate of myocardial infarction (MI) (p?=?0.17) and revascularization (p?=?0.12). At 5 years, CABG was favored due to a significantly lower rate of MACCE (OR, 1.67; 95% CI, 1.18-2.36; p?=?<0.04), MI (OR, 1.67; 95% CI, 1.35-2.06; p?=?<0.00001), and revascularization (OR, 2.80; 95% CI, 2.18-3.60; p?=?<0.00001), respectively. PCI was associated with a lower overall rate of a stroke, while the risk of all-cause mortality was not significantly different between the two groups at 1- (p?=?0.75), 5- (p?=?0.72), and 10-years (p?=?0.20). The Kaplan-Meier curve reconstruction revealed substantial variations over time; the 5-year incidence of MACCE was 38% with CABG, significantly lower than 45% with PCI (p?=?<0.00001). Conclusion:PCI might offer early safety advantages, while CABG provides greater durability in terms of lower long-term risk of ischemic events. There appears to be an equivalent risk for all-cause mortality.

SUBMITTER: Ullah W 

PROVIDER: S-EPMC7399756 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5730452 | BioStudies
2019-01-01 | S-EPMC6837018 | BioStudies
2017-01-01 | S-EPMC5662302 | BioStudies
1000-01-01 | S-EPMC5839846 | BioStudies
2015-01-01 | S-EPMC4944845 | BioStudies
2014-01-01 | S-EPMC4262069 | BioStudies
2020-01-01 | S-EPMC7408984 | BioStudies
2020-01-01 | S-EPMC6961598 | BioStudies
2018-01-01 | S-EPMC5754943 | BioStudies
1000-01-01 | S-EPMC5940397 | BioStudies